| 產(chǎn)品名稱 | MLN 2238 - Ixazomib |
| 產(chǎn)品貨號(hào) | Axon 2556 CAS [1072833-77-2] MF C14H19BCl2N2O4MW 361.03 Purity: 98% Solubble in DMSO Description Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.? MLN 2238 is also available as the more stable citrate prodrug MLN 9708 (Axon 2557). KEYWORDS:?MLN 2238 | supplier | Proteasome inhibitor | Ixazomib | MLN2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708 |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
MLN 2238 - IxazomibAxon 2556 CAS [1072833-77-2] MF C14H19BCl2N2O4
DescriptionSelective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN 2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.? MLN 2238 is also available as the more stable citrate prodrug MLN 9708 (Axon 2557). KEYWORDS:?MLN 2238 | supplier | Proteasome inhibitor | Ixazomib | MLN2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708
Selective and reversible 20S proteasome inhibitor
Chemical name(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Parent CAS No.[1072833-77-2] |
| 產(chǎn)品資料 |
